Agenix cuts COO position

By Ruth Beran
Thursday, 27 October, 2005

Brad Calvin is to step down as chief operating officer of Agenix (ASX:AGX) today after the company decided not to renew his employment contract.

Agenix managing director Donald Home will take on Calvin's responsibilities.

The company said Calvin was initially employed to lead the sales and marketing of the Agenix's Animal Health, Human Health and Milton Pharmaceuticals businesses and to assist in the commercialisation of the company's ThromboView product.

Agenix has since divested Milton Pharmaceuticals and entered into an agreement for the global sales, marketing and distribution of ThromboView and the company decided that its requirements for the Animal and Human Health businesses "did not warrant the current level of staffing".

Related News

Oxytocin analogue treats chronic abdominal pain

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd